Avid Bioservices to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Avid Bioservices, Inc. (NASDAQ:CDMO) announced its participation in two investor conferences taking place in September 2021. The company will engage in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, followed by 1-on-1 meetings from September 9-10 and 13-15. Avid will also present at the HC Wainwright 23rd Annual Global Investment Conference on September 13, with a corporate presentation available online at 7:00 a.m. Eastern. Both events feature virtual formats.

TUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that the company will participate in two upcoming investor conferences.

Details of the company’s participation are as follows:

• Morgan Stanley 19^th Annual Global Healthcare Conference
  Details: Avid management will participate in a fireside chat and 1-on-1 meetings
  Conference Dates: September 9-10 and 13-15, 2021
  Fireside Chat Timing: 2:45 – 3:15 p.m. Eastern on Thursday, September 9, 2021
  Format: Virtual conference; webcast available

• HC Wainwright 23^rd Annual Global Investment Conference
  Details: Avid management will deliver a corporate presentation and participate in 1-on-1 meetings
  Conference Dates: September 13-15, 2021
  Presentation Timing: Available online at 7:00 a.m. Eastern on Monday, September 13, 2021
  Format: Virtual conference
  

To listen to the live webcast of the Morgan Stanley fireside chat, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

FAQ

What are the dates for Avid Bioservices' upcoming investor conferences in September 2021?

The investor conferences are scheduled for September 9-10 and 13-15, 2021.

When will Avid Bioservices participate in the Morgan Stanley conference?

Avid will participate in a fireside chat on September 9, 2021, from 2:45 to 3:15 p.m. Eastern.

How can I access the live webcast of Avid Bioservices' fireside chat?

The live webcast can be accessed via Avid Bioservices' investor events page.

What will Avid Bioservices present at the HC Wainwright conference?

Avid will deliver a corporate presentation and participate in 1-on-1 meetings on September 13-15, 2021.

What is the focus of Avid Bioservices as a CDMO?

Avid Bioservices specializes in the development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell cultures.